Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

Once-weekly basal insulin combined with an intermittently scanned continuous glucose monitor reduced HbA1c and improved time ...

Novo Nordisk ... treatment known as an amylin analog — and semaglutide, the active ingredient in Wegovy. It was hoped that the drug would offer improved weight loss for patients with diabetes ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

Novo Nordisk has ... to diversify its obesity range. "Novo Nordisk is dedicated to providing improved treatment options for people living with obesity, type 2 diabetes, and other cardiometabolic ...

Novo Nordisk ... diabetes treatment following CagriSema's latest results. However, Soren Lontoft, pharma equity analyst at Sydbank, told CNBC last week that there was need for a diverse range ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

There's no doubt that self-injection devices have transformed the lives of people with chronic diseases like diabetes ... range of items, such as chairs, lamps, and other glassware. "Novo Nordisk ...

Diabetes treatment has advanced since several diabetes organizations united to recommend a “time in range” target of ... MannKind, Novo Nordisk, and Sanofi. Carlson had no personal financial ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...